We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Glaukos (GKOS) Q4 Earnings and Revenues Surpass Estimates
Read MoreHide Full Article
Glaukos Corporation (GKOS - Free Report) reported fourth-quarter loss per share of 6 cents, narrower than the Zacks Consensus Estimate of a loss of 17 cents. Notably, the company had delivered earnings per share of 8 cents a year ago.
For the full-year 2019, the company reported loss per share of 10 cents, narrower than the year-ago quarter’s loss of 29 cents per share.
Revenues in Detail
The Zacks Rank #3 (Hold) company’s quarterly net sales totaled $65.9 million, which beat the Zacks Consensus Estimate by 4.4%. On a year-over-year basis, revenues improved 21.8%. Per management, the upside can be attributed to Glaucoma unit volume increases worldwide and contribution from the Avedro buyout.
For the full-year 2019, the company reported net sales of $236.9 million, up 30.7% from that of 2018.
Glaukos Corporation Price, Consensus and EPS Surprise
Gross profit in the fourth quarter was $49.9 million, up 6.4% year over year. Gross margin quarter was 75.8% of net revenues, down 1100 basis points on a year-over-year basis.
Operating expenses increased 76.7% to $79.6 million on a year-over-year basis courtesy of higher selling, general and administrative, and research and development expenses.
Financial Update
As of Dec 31, 2019, cash and cash equivalents came in at $62.4 million, which increased significantly from the year-ago quarter.
During the fourth quarter, total assets came in at $818.4 million compared with $206.9 million in the year-ago quarter.
2020 Guidance
Glaukos expects revenues in the range of $290-$300 million. The Zacks Consensus Estimate is pegged at $316 million.
Our Take
Glaukos exited the fourth quarter on a strong note. Strong revenue outlook for 2020 instills optimism in the stock. The company witnessed another solid quarter that marked the end of a transformative year of 2019, reflecting substantial growth at its global Glaucoma franchise, advancement in its market-expanding pipeline and execution of quite a few business development growth initiatives that includes the buyout of Avedro.
Meanwhile, surging operating expenses remain a concern. Glaukos also faces cut-throat competition in the Medical Devices space. The company also witnessed a contraction in its gross margin in the quarter under review.
Stryker delivered fourth-quarter 2019 adjusted EPS of $2.49, outpacing the Zacks Consensus Estimate by 1.2%. Fourth-quarter reported revenues of $4.13 billion surpassed the Zacks Consensus Estimate by 0.7%. The company carries a Zacks Rank #2 (Buy).
Accuray reported second-quarter fiscal 2020 adjusted earnings per share (EPS) of a penny, beating the Zacks Consensus Estimate of a loss of 7 cents. Net revenues of $98.8 million outpaced the Zacks Consensus Estimate by 0.3%. The company sports a Zacks Rank #1.
IDEXX Laboratories reported fourth-quarter 2019 adjusted EPS of $1.04, which beat the Zacks Consensus Estimate of 91 cents by 14.3%. Revenues were $605.4 million, surpassing the Zacks Consensus Estimate by 0.9%. The company carries a Zacks Rank of 2.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Glaukos (GKOS) Q4 Earnings and Revenues Surpass Estimates
Glaukos Corporation (GKOS - Free Report) reported fourth-quarter loss per share of 6 cents, narrower than the Zacks Consensus Estimate of a loss of 17 cents. Notably, the company had delivered earnings per share of 8 cents a year ago.
For the full-year 2019, the company reported loss per share of 10 cents, narrower than the year-ago quarter’s loss of 29 cents per share.
Revenues in Detail
The Zacks Rank #3 (Hold) company’s quarterly net sales totaled $65.9 million, which beat the Zacks Consensus Estimate by 4.4%. On a year-over-year basis, revenues improved 21.8%. Per management, the upside can be attributed to Glaucoma unit volume increases worldwide and contribution from the Avedro buyout.
For the full-year 2019, the company reported net sales of $236.9 million, up 30.7% from that of 2018.
Glaukos Corporation Price, Consensus and EPS Surprise
Glaukos Corporation price-consensus-eps-surprise-chart | Glaukos Corporation Quote
Quarter Details
Gross profit in the fourth quarter was $49.9 million, up 6.4% year over year. Gross margin quarter was 75.8% of net revenues, down 1100 basis points on a year-over-year basis.
Operating expenses increased 76.7% to $79.6 million on a year-over-year basis courtesy of higher selling, general and administrative, and research and development expenses.
Financial Update
As of Dec 31, 2019, cash and cash equivalents came in at $62.4 million, which increased significantly from the year-ago quarter.
During the fourth quarter, total assets came in at $818.4 million compared with $206.9 million in the year-ago quarter.
2020 Guidance
Glaukos expects revenues in the range of $290-$300 million. The Zacks Consensus Estimate is pegged at $316 million.
Our Take
Glaukos exited the fourth quarter on a strong note. Strong revenue outlook for 2020 instills optimism in the stock. The company witnessed another solid quarter that marked the end of a transformative year of 2019, reflecting substantial growth at its global Glaucoma franchise, advancement in its market-expanding pipeline and execution of quite a few business development growth initiatives that includes the buyout of Avedro.
Meanwhile, surging operating expenses remain a concern. Glaukos also faces cut-throat competition in the Medical Devices space. The company also witnessed a contraction in its gross margin in the quarter under review.
Earnings of Other MedTech Majors at a Glance
Some better-ranked stocks that reported solid results this earning season are Stryker Corporation (SYK - Free Report) , Accuray Incorporated (ARAY - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) . You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Stryker delivered fourth-quarter 2019 adjusted EPS of $2.49, outpacing the Zacks Consensus Estimate by 1.2%. Fourth-quarter reported revenues of $4.13 billion surpassed the Zacks Consensus Estimate by 0.7%. The company carries a Zacks Rank #2 (Buy).
Accuray reported second-quarter fiscal 2020 adjusted earnings per share (EPS) of a penny, beating the Zacks Consensus Estimate of a loss of 7 cents. Net revenues of $98.8 million outpaced the Zacks Consensus Estimate by 0.3%. The company sports a Zacks Rank #1.
IDEXX Laboratories reported fourth-quarter 2019 adjusted EPS of $1.04, which beat the Zacks Consensus Estimate of 91 cents by 14.3%. Revenues were $605.4 million, surpassing the Zacks Consensus Estimate by 0.9%. The company carries a Zacks Rank of 2.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>